Catalyst overview
Research summary
This catalyst tracks a Phase 3 update for XPOVIO (Selinexor) (XPO1 inhibitor) in Endometrial cancer. The expected timing is based on the latest available company guidance and may change.
05/14/26:- XPORT-EC-042 enrollment completed; top-line data still expected Mid-2026. 07/30/26:- XPORT-EC-042 Ph3 topline results missed PFS endpoint; data presentation planned at future meeting. 08/13/26:- XPORT-EC-042 missed PFS endpoint; long-term follow-up continues.
Verification
Confirm timing and program details against the company announcement or filing.